Does Blue Cross Blue Shield of Massachusetts Cover Forteo?

What Is Forteo and Why Does Coverage Get Complicated?

Teriparatide, sold as Forteo and manufactured by Eli Lilly, is a recombinant form of the first 34 amino acids of human parathyroid hormone. Unlike bisphosphonates, which slow bone breakdown, teriparatide actively builds new bone by stimulating osteoblast activity. The FDA approved teriparatide in 2002 for postmenopausal women and men with osteoporosis at high fracture risk, and subsequently for glucocorticoid-induced osteoporosis.

The complexity around insurance coverage stems from two realities operating at once. First, Forteo carries one of the highest list prices among outpatient osteoporosis drugs, which pushes it onto specialty tiers with meaningful cost-sharing. Second, equally effective, far cheaper bisphosphonates like alendronate (generic, roughly $10-$30/month) exist as first-line agents in every major guideline. The 2020 American Association of Clinical Endocrinologists and American College of Endocrinology Clinical Practice Guidelines for Diagnosis and Treatment of Postmenopausal Osteoporosis designate teriparatide as a preferred agent only for very high-risk patients, specifically those with T-scores below -3.0, multiple prior fragility fractures, or documented intolerance or treatment failure on antiresorptive therapy.

That clinical reality gives BCBS Massachusetts the grounds to impose step therapy. Plans are not denying Forteo because it does not work. They are requiring evidence that cheaper options were genuinely tried first.

How BCBS Massachusetts Formularies Classify Forteo

BCBS MA operates several distinct plan lines: HMO Blue, Blue Choice, PPO, and plans offered through the Massachusetts Health Connector (Commonwealth Care and ConnectorCare). Each has its own formulary, and the drug tier assigned to teriparatide can differ between them.

On most commercial HMO Blue and Blue Choice plans as of 2025, brand-name Forteo sits on Tier 4 or Tier 5 (specialty). Tier 4 cost-sharing on a typical HMO Blue plan runs 25-40% coinsurance after the deductible, which on a $3,200 list-price medication translates to $800-$1,280 out of pocket per month without a copay cap. Specialty tier designs, however, frequently include out-of-pocket maximum protections, so members who reach their annual maximum pay $0 for the remainder of the calendar year.

Generic teriparatide (approved by the FDA in 2019) may be placed on a lower tier than brand Forteo on some BCBS MA formularies. If your prescriber writes for brand Forteo specifically, the plan may require a dispense-as-written override to avoid an automatic substitution to the generic, or conversely may require a brand-necessary exception if the formulary only lists the generic. Confirm with BCBS MA pharmacy services at 1-800-262-2583 which version is on your specific plan's formulary before the prescription is sent.

Medicare Advantage plans administered by BCBS MA (such as Medicare Blue) place teriparatide on Part D Tier 5 in most benefit designs. Under Medicare Part D, Tier 5 specialty drugs have fixed copay or coinsurance structures governed by CMS, and 2025 Part D out-of-pocket caps ($2,000 annually under the Inflation Reduction Act changes) provide meaningful protection for long-term users.

Prior Authorization Criteria: What BCBS Massachusetts Actually Requires

Prior authorization (PA) for Forteo under BCBS MA commercial plans generally requires all of the following to be documented by the prescribing physician:

Diagnosis confirmation. A DEXA scan showing a T-score of -2.5 or below at the lumbar spine or femoral neck, or a T-score of -1.0 or below with a prior low-trauma fracture. The scan must have been performed within the past 24 months in most criteria sets.

Step therapy completion. Documentation that the patient received an adequate trial of at least one oral bisphosphonate, typically alendronate 70 mg weekly or risedronate 35 mg weekly, for a minimum of 6-12 months, and either experienced a new fracture on therapy, demonstrated no improvement or decline in bone density on serial DEXA, or had a documented contraindication or adverse effect (typically esophageal stricture, severe renal impairment with creatinine clearance <35 mL/min, or bisphosphonate-related osteonecrosis of the jaw).

High-risk designation. The Endocrine Society's 2019 Clinical Practice Guideline on Osteoporosis in Postmenopausal Women reserves anabolic agents for patients at "imminent fracture risk," defined as a FRAX 10-year major osteoporotic fracture probability above 20% or prior vertebral or hip fracture. BCBS MA criteria align closely with this threshold.

Prescriber specialty. Some BCBS MA PA criteria require or prefer that the prescribing physician be an endocrinologist, rheumatologist, or other specialist rather than a primary care provider, particularly when the step therapy requirement is being bypassed on clinical grounds.

The PA is typically approved for 6 months initially, then renewed for an additional 6-month period to complete the FDA-labeled 24-month course. Renewals require documentation of treatment compliance and confirmation that the cumulative duration does not exceed 24 months lifetime, as the FDA's boxed warning restricts total teriparatide exposure based on osteosarcoma risk data from rat studies (though no causal link to human osteosarcoma has been established in post-marketing surveillance).

Step Therapy: What Counts as a Qualifying Prior Treatment?

Step therapy policies for Forteo under BCBS MA generally accept the following as qualifying prior treatments:

Oral bisphosphonates (alendronate, risedronate, ibandronate) taken for at least 6 months at guideline-recommended doses. Intravenous zoledronic acid (Reclast) 5 mg annually may also satisfy the step therapy requirement on certain plan designs, which matters for patients who cannot tolerate oral agents due to upper GI conditions.

Denosumab (Prolia) 60 mg subcutaneous every 6 months, while not a bisphosphonate, may satisfy step therapy on some BCBS MA criteria sets as an antiresorptive alternative. Check the specific coverage determination letter for your plan.

Raloxifene (Evista) is listed as a step therapy option in some PA criteria, though AACE guidelines note it is less potent than bisphosphonates and primarily reduces vertebral fracture risk without demonstrated hip fracture reduction. If your plan lists raloxifene as a required step, you may have grounds to appeal on clinical appropriateness, particularly if hip fracture risk is high.

Romosozumab (Evenity) is a separate anabolic/antiresorptive agent. It is not typically listed as a step therapy prerequisite for Forteo, as both drugs occupy the anabolic class. Switching between anabolic agents requires separate clinical justification.

The HealthRX clinical team has developed the following practical framework for patients and prescribers pursuing Forteo authorization at BCBS MA:

Step 1. Obtain a baseline DEXA with T-scores reported at both the lumbar spine and total hip. Ensure the scan is dated within 24 months of the PA submission.

Step 2. Document the bisphosphonate trial in the medical record with specific start date, dose, and duration. If the trial was stopped for an adverse event, record the event with ICD-10 coding (e.g., M27.59 for osteonecrosis, K22.10 for esophageal ulcer).

Step 3. Calculate and document FRAX scores in the office note. BCBS MA reviewers respond to explicit numeric risk thresholds, not qualitative descriptions.

Step 4. If the patient has a prior vertebral fracture, document it with imaging (X-ray or MRI) and include the radiology report in the PA submission. Vertebral fracture history is among the strongest predictors of PA approval without full step therapy completion.

Step 5. Submit via the BCBS MA provider portal (ProviderOne) with CPT code J3110 (teriparatide injection, 10 mcg) or the applicable NDC for the pen device. Include a Letter of Medical Necessity signed by the prescriber.

What Happens After a Denial: The Appeals Process

BCBS MA must comply with Massachusetts General Law Chapter 176O, which governs managed care plan grievances and appeals. A first-level internal appeal must be filed within 180 days of a denial notice. The plan has 30 days to issue a written decision on standard appeals, or 72 hours for urgent/expedited appeals.

For Forteo denials, the most effective appeal arguments are:

Bisphosphonate contraindication. Oral bisphosphonates are contraindicated in patients with a creatinine clearance <35 mL/min per the FDA prescribing information for alendronate. If renal function precludes bisphosphonate use, document serum creatinine and calculated GFR in the appeal letter.

Fracture on therapy. A new vertebral or hip fracture documented by imaging while the patient was adherent to bisphosphonate therapy is one of the strongest grounds for bypassing or abbreviating step therapy requirements. Include imaging reports and prescription fill history from the pharmacy.

Prior fracture burden. The NEJM Black et al. teriparatide trial (N=1,637) demonstrated a 65% relative risk reduction in new vertebral fractures (P<0.001) over 21 months versus placebo in postmenopausal women with prior vertebral fractures. Citing this trial in an appeal letter with the patient's matching fracture history strengthens the medical necessity argument substantially.

Independent External Review. If the internal appeal is denied, Massachusetts law entitles members to request an Independent External Review through the Massachusetts Division of Insurance. External reviewers are physicians unaffiliated with BCBS MA. For anabolic osteoporosis agents, external reviewers tend to apply AACE and Endocrine Society clinical criteria rather than insurer step therapy policies, which often favors the patient when genuine high-risk features are present.

Forteo vs. Generic Teriparatide: Does the Plan Prefer One Over the Other?

The FDA approved the first generic teriparatide injection (from Alvogen) in 2019 under the 505(b)(2) pathway. BCBS MA commercial formularies have responded differently over time. Some plans list only the generic as covered and require a brand exception for Forteo specifically. Others list both but apply a higher cost-sharing tier to brand Forteo.

From a clinical standpoint, the FDA's approval of generic teriparatide was based on demonstration of bioequivalence, meaning the pharmacokinetic profile of the generic matches Forteo's. The injection device differs from the original Lilly pen, which can be relevant for patients with dexterity limitations or those who find device training on the brand pen easier to follow.

If your prescriber has a clinical reason to prefer the brand pen (device compatibility, patient familiarity with existing training), a formulary exception citing device-specific rationale can be submitted alongside the standard PA. These exceptions are granted less reliably than medical necessity arguments, but they succeed in a meaningful subset of cases.

Manufacturer Patient Assistance and Savings Programs

Even after a successful PA, Tier 4-5 cost-sharing can be financially prohibitive. Two programs reduce out-of-pocket expense for eligible patients:

Lilly Cares Foundation. For commercially uninsured or underinsured patients meeting income criteria (generally household income at or below 400% of the federal poverty level), the Lilly Cares Foundation provides Forteo at no cost. Applications are submitted through the prescriber's office. Processing takes 2-4 weeks.

Lilly Insulin Value Program / Savings Card. Commercially insured patients with incomes above the Lilly Cares threshold may be eligible for a copay savings card that reduces out-of-pocket cost to as low as $0-$25 per month for up to 24 months. The card cannot be used for Medicare or Medicaid beneficiaries due to federal anti-kickback statute restrictions. Confirm eligibility at Lilly's official patient support page.

Massachusetts also operates MassHealth (Medicaid), and teriparatide coverage under MassHealth is governed by the MassHealth Pharmacy Program's Preferred Drug List, which is separate from BCBS MA commercial formularies and imposes its own PA criteria.

Clinical Context: When Is Forteo the Right Choice?

Understanding why BCBS MA requires step therapy becomes clearer when placed against the clinical evidence.

Alendronate 70 mg weekly reduces vertebral fracture risk by approximately 47% and hip fracture risk by approximately 51% relative to placebo over 3 years, per the FIT trial, at a cost of roughly $10-$30/month generic. For most patients with osteoporosis who are bisphosphonate-tolerant, that is a highly cost-effective intervention.

Teriparatide adds anabolic benefit in patients where antiresorptive therapy has been insufficient. The Black et al. NEJM trial mentioned above showed a 65% relative risk reduction in new vertebral fractures over 21 months in women with established vertebral fracture disease. A subsequent Cochrane systematic review (Neer et al. data, Cochrane Library 2022) confirmed teriparatide's superiority to antiresorptive agents in patients at very high fracture risk.

The Endocrine Society's 2019 guidelines state explicitly: "We suggest anabolic therapy be considered as initial therapy in patients with very high risk for fracture," defining very high risk as T-score below -3.0 or multiple fractures or both. When a patient meets that threshold at baseline, a prescriber can argue that step therapy itself poses fracture risk and that bypassing it is medically necessary. This argument, backed by DEXA data and imaging, succeeds in appeals with regularity.

Practical Next Steps for Patients

Start the process at your prescriber's office, not the pharmacy. The PA for Forteo requires physician-generated clinical documentation that a pharmacist cannot produce. Ask your prescriber to use the BCBS MA PA form for specialty biologics and to attach the DEXA report, the FRAX score, fracture imaging if applicable, and a summary of prior bisphosphonate therapy.

Request a peer-to-peer review if the initial PA is denied. BCBS MA medical directors are required to speak with the treating physician before an adverse determination becomes final on non-urgent cases. Many denials reverse at this stage when an endocrinologist presents the fracture burden directly.

Check the BCBS MA online formulary tool at bcbsma.com to verify whether brand Forteo or generic teriparatide is listed for your specific plan and benefit year, as formularies update annually on January 1.

The FDA-labeled maximum treatment duration of 24 months means the coverage battle has a finite timeline. A patient who secures authorization in month one and maintains PA renewals will complete a full anabolic course before switching to sequential antiresorptive therapy. The American Society for Bone and Mineral Research recommends following teriparatide with 12-24 months of antiresorptive therapy (typically zoledronic acid or denosumab) to preserve the bone density gains made during the anabolic phase.